首页 > 最新文献

Journal of Osteoporosis最新文献

英文 中文
Changes in Testing and Treatment Methods in Osteoporosis Care 骨质疏松症护理中检测和治疗方法的变化
IF 1.9 Q3 Medicine Pub Date : 2024-04-17 DOI: 10.1155/2024/9629891
T. Nagai, K. Ishikawa, Koki Tsuchiya, Soji Tani, Yusuke Dodo, Y. Oshita, Keizo Sakamoto, Nobuyuki Kawate, Yoshifumi Kudo
Osteoporosis treatment plays a crucial role in preventing fractures, particularly in bedridden patients. We conducted a questionnaire survey presenting hypothetical clinical cases in 2015 and 2020 to investigate trends over a 5-year period. The target population included physicians working in clinics and hospitals within our neighbourhood. The cases were presented, and the questionnaire was administered in a confidential format. The orthopaedic surgeons were matched for age and practice, resulting in 74 cases being included in the analysis. Comparing the 2015 and 2020 results, we observed a notable increase in physicians who would perform “bone mineral density measurements of the lumbar spine and hip.” Furthermore, there was a significant rise in the percentage of respondents willing to test for bone metabolic markers, such as serum type I collagen cross-linked N-telopeptide (NTX), procollagen I N-terminal propeptide (P1NP), and tartrate-resistant acid phosphatase 5b (TRACP-5b). Regarding therapeutic agents, bisphosphonates decreased in usage, whereas parathyroid hormone and romosozumab witnessed an increase. In conclusion, the percentage of physicians requesting bone mineral density measurements of the lumbar spine and hip increased over the five-year period. In addition, more physicians chose to utilise bone metabolic markers due to their ease of measurement through blood tests and reduced diurnal variation. Finally, there was a marked trend towards the administration of drugs capable of rapidly and effectively increasing bone mineral density at an early stage of treatment.
骨质疏松症治疗在预防骨折方面起着至关重要的作用,尤其是对卧床不起的患者。我们对 2015 年和 2020 年的假设临床病例进行了问卷调查,以研究 5 年间的趋势。调查对象包括我们周边诊所和医院的医生。病例以保密形式呈现,问卷以保密形式发放。骨科外科医生的年龄和执业范围均匹配,因此有 74 个病例被纳入分析。对比 2015 年和 2020 年的结果,我们发现会进行 "腰椎和髋部骨矿密度测量 "的医生明显增多。此外,愿意检测骨代谢标志物(如血清 I 型胶原交联 N-telopeptide (NTX)、I 型胶原 N-terminal propeptide (P1NP)、抗酒石酸磷酸酶 5b (TRACP-5b))的受访者比例也有显著上升。在治疗药物方面,双膦酸盐的使用率有所下降,而甲状旁腺激素和罗莫索单抗的使用率有所上升。总之,要求进行腰椎和髋部骨矿密度测量的医生比例在五年内有所增加。此外,更多的医生选择使用骨代谢标记物,因为这些标记物易于通过血液化验进行测量,而且昼夜变化较小。最后,一个明显的趋势是在治疗的早期阶段使用能够快速有效增加骨矿物质密度的药物。
{"title":"Changes in Testing and Treatment Methods in Osteoporosis Care","authors":"T. Nagai, K. Ishikawa, Koki Tsuchiya, Soji Tani, Yusuke Dodo, Y. Oshita, Keizo Sakamoto, Nobuyuki Kawate, Yoshifumi Kudo","doi":"10.1155/2024/9629891","DOIUrl":"https://doi.org/10.1155/2024/9629891","url":null,"abstract":"Osteoporosis treatment plays a crucial role in preventing fractures, particularly in bedridden patients. We conducted a questionnaire survey presenting hypothetical clinical cases in 2015 and 2020 to investigate trends over a 5-year period. The target population included physicians working in clinics and hospitals within our neighbourhood. The cases were presented, and the questionnaire was administered in a confidential format. The orthopaedic surgeons were matched for age and practice, resulting in 74 cases being included in the analysis. Comparing the 2015 and 2020 results, we observed a notable increase in physicians who would perform “bone mineral density measurements of the lumbar spine and hip.” Furthermore, there was a significant rise in the percentage of respondents willing to test for bone metabolic markers, such as serum type I collagen cross-linked N-telopeptide (NTX), procollagen I N-terminal propeptide (P1NP), and tartrate-resistant acid phosphatase 5b (TRACP-5b). Regarding therapeutic agents, bisphosphonates decreased in usage, whereas parathyroid hormone and romosozumab witnessed an increase. In conclusion, the percentage of physicians requesting bone mineral density measurements of the lumbar spine and hip increased over the five-year period. In addition, more physicians chose to utilise bone metabolic markers due to their ease of measurement through blood tests and reduced diurnal variation. Finally, there was a marked trend towards the administration of drugs capable of rapidly and effectively increasing bone mineral density at an early stage of treatment.","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140693489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment 罗莫单抗治疗骨质疏松症后的转换疗法与之前治疗的效果比较
IF 1.9 Q3 Medicine Pub Date : 2024-01-09 DOI: 10.1155/2024/2144527
Akira Horikawa, Y. Kasukawa, Michio Hongo, A. Sano, N. Miyakoshi
Rationale. Although romosozumab is one of the most effective treatments for osteoporosis by increasing bone mineral density in the lumbar spine and femur and recommended for denosumab as switch therapy, these effects regarding its prior treatment have not yet been evaluated clearly. This study focused on the effects of switch therapy from romosozumab to denosumab in regard to prior treatment of osteoporosis including bone mineral density and bone turnover marker and other related factors. Patient Concerns. 15 osteoporotic patients were assigned to the naïve group, 15 were assigned to the teriparatide group, and 10 were assigned to the bisphosphonate group. Interventions. Patients who were treated as outpatients for osteoporosis with romosozumab for 1 year and switched to denosumab between 2020 and 2022 at our hospital were examined. Our hospital registry included 40 osteoporotic patients who were over 65 years of age with bone mineral density (bone mineral density): T score <−2.5 standard deviations (SDs) and fracture assessment tool (FRAX) score >20%. Outcomes. The naïve group had the highest increase in LS BMD among these three groups during switch therapy from romosozumab to denosumab, while there were no significant differences about adverse drug events and serum Ca concentration among them. There was no incidence of fracture. Conclusion. These findings indicate that the effects of osteoporotic treatment of switch therapy from romosozumab to denosumab were likely to affect prior treatment of osteoporosis.
理由尽管罗莫司单抗是治疗骨质疏松症最有效的药物之一,能增加腰椎和股骨的骨矿密度,并被推荐作为地诺单抗的转换疗法,但其对之前治疗的影响尚未得到明确评估。本研究重点关注从罗莫司单抗到地诺单抗的转换疗法对之前治疗骨质疏松症的影响,包括骨矿密度和骨转换标志物及其他相关因素。关注患者。15 名骨质疏松症患者被分配到新药组,15 名被分配到特立帕肽组,10 名被分配到双膦酸盐组。干预。研究对象为在本医院门诊接受罗莫索单抗治疗1年的骨质疏松症患者,在2020年至2022年期间改用地诺单抗治疗。我们医院的登记册纳入了 40 名骨质疏松症患者,他们的年龄都在 65 岁以上,骨矿密度(bone mineral density:)T 评分 20%。结果。从罗莫单抗到地诺单抗的转换治疗过程中,三组患者中天真组的LS BMD增加率最高,而三组患者在药物不良反应和血清Ca浓度方面无显著差异。无骨折发生。结论这些研究结果表明,从罗莫单抗到地诺单抗的转换疗法对骨质疏松症治疗的影响很可能会影响到之前的骨质疏松症治疗。
{"title":"The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment","authors":"Akira Horikawa, Y. Kasukawa, Michio Hongo, A. Sano, N. Miyakoshi","doi":"10.1155/2024/2144527","DOIUrl":"https://doi.org/10.1155/2024/2144527","url":null,"abstract":"Rationale. Although romosozumab is one of the most effective treatments for osteoporosis by increasing bone mineral density in the lumbar spine and femur and recommended for denosumab as switch therapy, these effects regarding its prior treatment have not yet been evaluated clearly. This study focused on the effects of switch therapy from romosozumab to denosumab in regard to prior treatment of osteoporosis including bone mineral density and bone turnover marker and other related factors. Patient Concerns. 15 osteoporotic patients were assigned to the naïve group, 15 were assigned to the teriparatide group, and 10 were assigned to the bisphosphonate group. Interventions. Patients who were treated as outpatients for osteoporosis with romosozumab for 1 year and switched to denosumab between 2020 and 2022 at our hospital were examined. Our hospital registry included 40 osteoporotic patients who were over 65 years of age with bone mineral density (bone mineral density): T score <−2.5 standard deviations (SDs) and fracture assessment tool (FRAX) score >20%. Outcomes. The naïve group had the highest increase in LS BMD among these three groups during switch therapy from romosozumab to denosumab, while there were no significant differences about adverse drug events and serum Ca concentration among them. There was no incidence of fracture. Conclusion. These findings indicate that the effects of osteoporotic treatment of switch therapy from romosozumab to denosumab were likely to affect prior treatment of osteoporosis.","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139442765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative MR Analysis of Changes in the Radius Bone Marrow in Osteoporosis. 骨质疏松症患者桡骨骨髓变化的磁共振定量分析
IF 1.9 Q3 Medicine Pub Date : 2023-12-27 eCollection Date: 2023-01-01 DOI: 10.1155/2023/7861495
Tamar K De-Levie, Yael S Schiffenbauer, Ido Druckmann, Vanessa Rouach, Naftali Stern, Itzhak Binderman, Uri Nevo

Purpose: This pilot study aimed to explore the feasibility of scanning the human distal radius bone marrow in vivo to detect osteoporosis-related changes using magnetic resonance and evaluate whether the radius may serve as an accessible probing site for osteoporosis. This may lead in the future to the use of affordable means such as low-field MRI scanners for the monitoring of disease progression.

Methods: A clinical trial was performed using a 3T MR scanner, including 26 women assigned into three study groups: healthy-premenopausal (n = 7; mean age 48.6 ± 3.5 years), healthy-postmenopausal (n = 10; mean age 54.5 ± 5.6 years), and osteoporotic-postmenopausal (n = 9; mean age 61.3 ± 5.6 years). Marrow fat composition was evaluated using T2 maps, a two-compartment model of T1, and a Dixon pulse sequence.

Results: The osteoporotic group exhibited higher fat content than the other two groups and lower T2 values than the healthy-premenopausal group.

Conclusions: Osteoporosis-related changes in the composition of the distal radius bone marrow may be detected in vivo using MRI protocols. The scanning protocols chosen here can later be repeated using low-field MRI scanners, thus offering the potential for early detection and treatment monitoring, using an accessible, affordable means that may be applied in small clinics. This trial is registered with MOH_2018-05-23_002247, NCT03742362.

目的:这项试验性研究旨在探索利用磁共振扫描人体桡骨远端骨髓以检测骨质疏松症相关变化的可行性,并评估桡骨是否可作为骨质疏松症的可探查部位。这可能导致未来使用低场磁共振成像扫描仪等经济实惠的方法来监测疾病的进展:使用 3T 磁共振扫描仪进行了一项临床试验,将 26 名妇女分为三个研究组:绝经前健康组(7 人;平均年龄为 48.6 ± 3.5 岁)、绝经后健康组(10 人;平均年龄为 54.5 ± 5.6 岁)和绝经后骨质疏松症组(9 人;平均年龄为 61.3 ± 5.6 岁)。使用T2图、T1两室模型和迪克森脉冲序列评估骨髓脂肪组成:结果:骨质疏松症组的脂肪含量高于其他两组,T2值低于健康绝经组:结论:骨质疏松症相关的桡骨远端骨髓成分变化可通过核磁共振成像方案进行活体检测。本文所选的扫描方案可在以后使用低场磁共振成像扫描仪重复扫描,从而为早期检测和治疗监测提供了可能性,这种方法方便易用、价格低廉,可在小型诊所中使用。该试验已在 MOH_2018-05-23_002247、NCT03742362 上注册。
{"title":"Quantitative MR Analysis of Changes in the Radius Bone Marrow in Osteoporosis.","authors":"Tamar K De-Levie, Yael S Schiffenbauer, Ido Druckmann, Vanessa Rouach, Naftali Stern, Itzhak Binderman, Uri Nevo","doi":"10.1155/2023/7861495","DOIUrl":"10.1155/2023/7861495","url":null,"abstract":"<p><strong>Purpose: </strong>This pilot study aimed to explore the feasibility of scanning the human distal radius bone marrow in vivo to detect osteoporosis-related changes using magnetic resonance and evaluate whether the radius may serve as an accessible probing site for osteoporosis. This may lead in the future to the use of affordable means such as low-field MRI scanners for the monitoring of disease progression.</p><p><strong>Methods: </strong>A clinical trial was performed using a 3T MR scanner, including 26 women assigned into three study groups: healthy-premenopausal (<i>n</i> = 7; mean age 48.6 ± 3.5 years), healthy-postmenopausal (<i>n</i> = 10; mean age 54.5 ± 5.6 years), and osteoporotic-postmenopausal (<i>n</i> = 9; mean age 61.3 ± 5.6 years). Marrow fat composition was evaluated using T2 maps, a two-compartment model of T1, and a Dixon pulse sequence.</p><p><strong>Results: </strong>The osteoporotic group exhibited higher fat content than the other two groups and lower T2 values than the healthy-premenopausal group.</p><p><strong>Conclusions: </strong>Osteoporosis-related changes in the composition of the distal radius bone marrow may be detected in vivo using MRI protocols. The scanning protocols chosen here can later be repeated using low-field MRI scanners, thus offering the potential for early detection and treatment monitoring, using an accessible, affordable means that may be applied in small clinics. This trial is registered with MOH_2018-05-23_002247, NCT03742362.</p>","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10764646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139098920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa 接受 Taliglucerase Alfa 治疗的阿尔巴尼亚 1 型戈谢病患者的骨骼表现、骨痛和 BMD 变化
IF 1.9 Q3 Medicine Pub Date : 2023-12-04 DOI: 10.1155/2023/3254533
V. Velmishi, E. Troja, M. Tanka, D. Bali, E. Dervishi, A. Tako, Laurant Kollcaku, P. Cullufi
Gaucher disease is a rare, genetic lysosomal disorder leading to lipid accumulation and dysfunctions in multiple organs. Bone involvement is one of the most prevalent aspects of Gaucher disease. Pain, disability, and reduced quality of life remain the most frequent characteristics of bone involvement in Gaucher patients. Patients and Method. In this study, we will take into consideration data from 24 patients diagnosed with type 1 Gaucher disease. We followed them closely for six years in progress. At baseline, all patients started therapy with taliglucerase alfa at a mean dosage of 45 UI/kg; later, during the study, two of them switched their cure toward velaglucerase alfa. Before baseline evaluations, 12 patients had been treated with imiglucerase at variable duration times. At baseline, we performed an X-ray of long bones and the spine, and each year, different standard assessments were performed, such as bone pain, MRI of the vertebral spine and pelvis, and DEXA for bone density. Four patients left the study for various reasons, two of them at baseline and two others during year 3 (FU3). Results. At baseline, we had 8 children and 16 adults. The average age was 28.7 ± 16.5 SD years. The most frequent skeletal manifestations in our patients were reduction of tibial femoral space (40%), osteonecrosis (36%), and body vertebral reduction (32%). At baseline, 15 patients presented with bone pain to different degrees. Over the years, bone pain in our patients had a gradual improvement. The most dramatic bone pain improvement was seen in a patient who presented bone crises. Another impressive finding was a significant BMD improvement during six years of treatment. Our study showed a significant improvement in BMD comparing FU5 and baseline values (p = 0.0007). Especially children demonstrated a significant improvement in BMD (p = 0.00061) compared to adults (p = 0.3673). Mean BMD change was more indicative in switched patients (p = 0.0142) compared to naïve patients (p = 0.147). Conclusions. Skeletal manifestations are very different in Gaucher type 1 patients. In our study, as a result of long-term evaluations, it was noticed that the most frequent skeletal manifestation was a reduction of tibiofemoral space. Bone pain has gradually improved in all patients. Also, BMD values have been enhanced over six years of treatment, especially in children.
戈谢病是一种罕见的遗传性溶酶体疾病,导致多器官的脂质积累和功能障碍。骨受累是戈谢病最普遍的方面之一。疼痛、残疾和生活质量下降仍然是戈歇患者骨骼受累最常见的特征。患者和方法。在本研究中,我们将考虑24例诊断为1型戈谢病的患者的数据。我们密切关注了他们六年的进展。在基线时,所有患者开始使用平均剂量为45 iu /kg的taliglucerase α - fa治疗;后来,在研究过程中,其中两人将治疗方法改为velaglucerase α。在基线评估之前,12名患者在不同的持续时间内接受了imiglucerase治疗。在基线,我们对长骨和脊柱进行x光检查,每年进行不同的标准评估,如骨痛,脊柱和骨盆的MRI检查,骨密度的DEXA检查。4名患者因各种原因退出研究,其中2名在基线时,另外2名在第3年(FU3)。结果。在基线时,我们有8名儿童和16名成年人。平均年龄28.7±16.5 SD年。我们患者中最常见的骨骼表现是胫骨股间隙缩小(40%),骨坏死(36%)和椎体缩小(32%)。基线时,15例患者出现不同程度的骨痛。多年来,我们患者的骨痛逐渐得到改善。最显著的骨痛改善见于出现骨危机的患者。另一个令人印象深刻的发现是,在六年的治疗期间,骨密度显著改善。我们的研究显示,比较FU5和基线值,BMD有显著改善(p = 0.0007)。与成人(p = 0.3673)相比,儿童在骨密度方面表现出显著改善(p = 0.00061)。与naïve患者(p = 0.147)相比,切换组患者的平均骨密度变化更具指示性(p = 0.0142)。结论。戈歇1型患者的骨骼表现非常不同。在我们的研究中,作为长期评估的结果,我们注意到最常见的骨骼表现是胫股间隙缩小。所有患者骨痛均逐渐改善。此外,在六年的治疗中,骨密度值也有所提高,尤其是在儿童中。
{"title":"Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa","authors":"V. Velmishi, E. Troja, M. Tanka, D. Bali, E. Dervishi, A. Tako, Laurant Kollcaku, P. Cullufi","doi":"10.1155/2023/3254533","DOIUrl":"https://doi.org/10.1155/2023/3254533","url":null,"abstract":"Gaucher disease is a rare, genetic lysosomal disorder leading to lipid accumulation and dysfunctions in multiple organs. Bone involvement is one of the most prevalent aspects of Gaucher disease. Pain, disability, and reduced quality of life remain the most frequent characteristics of bone involvement in Gaucher patients. Patients and Method. In this study, we will take into consideration data from 24 patients diagnosed with type 1 Gaucher disease. We followed them closely for six years in progress. At baseline, all patients started therapy with taliglucerase alfa at a mean dosage of 45 UI/kg; later, during the study, two of them switched their cure toward velaglucerase alfa. Before baseline evaluations, 12 patients had been treated with imiglucerase at variable duration times. At baseline, we performed an X-ray of long bones and the spine, and each year, different standard assessments were performed, such as bone pain, MRI of the vertebral spine and pelvis, and DEXA for bone density. Four patients left the study for various reasons, two of them at baseline and two others during year 3 (FU3). Results. At baseline, we had 8 children and 16 adults. The average age was 28.7 ± 16.5 SD years. The most frequent skeletal manifestations in our patients were reduction of tibial femoral space (40%), osteonecrosis (36%), and body vertebral reduction (32%). At baseline, 15 patients presented with bone pain to different degrees. Over the years, bone pain in our patients had a gradual improvement. The most dramatic bone pain improvement was seen in a patient who presented bone crises. Another impressive finding was a significant BMD improvement during six years of treatment. Our study showed a significant improvement in BMD comparing FU5 and baseline values (p = 0.0007). Especially children demonstrated a significant improvement in BMD (p = 0.00061) compared to adults (p = 0.3673). Mean BMD change was more indicative in switched patients (p = 0.0142) compared to naïve patients (p = 0.147). Conclusions. Skeletal manifestations are very different in Gaucher type 1 patients. In our study, as a result of long-term evaluations, it was noticed that the most frequent skeletal manifestation was a reduction of tibiofemoral space. Bone pain has gradually improved in all patients. Also, BMD values have been enhanced over six years of treatment, especially in children.","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138603243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteoporosis Screening Disparities among Ethnic and Racial Minorities: A Systematic Review. 骨质疏松筛查在少数民族和种族之间的差异:一项系统综述。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/1277319
Anoush Calikyan, Jillian Silverberg, Katherine M McLeod

Background: Osteoporosis is a preventable disease that is simple and cost-effective to screen based on clinical practice guidelines, yet many patients go undiagnosed and untreated leading to increased burden of the disease. Specifically, racial and ethnic minorities have lower rates of dual energy absorptiometry (DXA) screening. Inadequate screening may lead to an increased risk of fracture, higher health care costs, and increased morbidity and mortality disproportionately experienced by racial-ethnic minority populations.

Purpose: This systematic review assessed and summarized the racial and ethnic disparities that exist for osteoporosis screening by DXA.

Methods: Using terms related to osteoporosis, racial and ethnic minorities, and DXA, an electronic search of databases was performed in SCOPUS, CINAHL, and PubMed. Articles were screened using predefined inclusion and exclusion criteria which dictated the final articles used in the review. Full text articles that were selected for inclusion underwent quality appraisal and data extraction. Once extracted, data from the articles were combined at an aggregate level.

Results: The search identified 412 articles. After screening, a total of 16 studies were included in the final review. The overall quality of the studies included was high. Of the 16 articles reviewed, 14 identified significant disparities between racial minority and majority groups and determined that the eligible patients in racial minority groups were less likely to be referred to DXA screening.

Conclusion: There is a significant disparity in osteoporosis screening among racial and ethnic minorities. Future efforts should focus on addressing these inconsistencies in screening and removing bias from the healthcare system. Additional research is required to determine the consequence of this discrepancy in screening and methods of equitizing osteoporosis care.

背景:骨质疏松症是一种可预防的疾病,根据临床实践指南进行筛查简单且具有成本效益,但许多患者未得到诊断和治疗,导致疾病负担增加。具体来说,种族和少数民族的双能量吸收仪(DXA)筛查率较低。筛查不充分可能导致骨折风险增加,医疗费用增加,发病率和死亡率增加,这在少数民族人口中是不成比例的。目的:本系统综述评估和总结了DXA筛查骨质疏松症存在的种族差异。方法:使用与骨质疏松症、少数民族和DXA相关的术语,对SCOPUS、CINAHL和PubMed数据库进行电子检索。文章使用预先确定的纳入和排除标准进行筛选,这些标准决定了在综述中使用的最终文章。选择纳入的全文文章进行了质量评估和数据提取。一旦提取出来,文章中的数据就会在聚合级别上进行组合。结果:检索到412篇文章。经筛选,最终纳入16项研究。纳入研究的总体质量很高。在回顾的16篇文章中,14篇确定了少数族裔和多数族裔之间的显著差异,并确定少数族裔中符合条件的患者不太可能被推荐进行DXA筛查。结论:少数民族骨质疏松筛查存在明显差异。未来的努力应集中在解决这些不一致的筛选和消除偏见从医疗保健系统。需要进一步的研究来确定这种筛查差异的后果和骨质疏松症护理方法的公平性。
{"title":"Osteoporosis Screening Disparities among Ethnic and Racial Minorities: A Systematic Review.","authors":"Anoush Calikyan,&nbsp;Jillian Silverberg,&nbsp;Katherine M McLeod","doi":"10.1155/2023/1277319","DOIUrl":"https://doi.org/10.1155/2023/1277319","url":null,"abstract":"<p><strong>Background: </strong>Osteoporosis is a preventable disease that is simple and cost-effective to screen based on clinical practice guidelines, yet many patients go undiagnosed and untreated leading to increased burden of the disease. Specifically, racial and ethnic minorities have lower rates of dual energy absorptiometry (DXA) screening. Inadequate screening may lead to an increased risk of fracture, higher health care costs, and increased morbidity and mortality disproportionately experienced by racial-ethnic minority populations.</p><p><strong>Purpose: </strong>This systematic review assessed and summarized the racial and ethnic disparities that exist for osteoporosis screening by DXA.</p><p><strong>Methods: </strong>Using terms related to osteoporosis, racial and ethnic minorities, and DXA, an electronic search of databases was performed in SCOPUS, CINAHL, and PubMed. Articles were screened using predefined inclusion and exclusion criteria which dictated the final articles used in the review. Full text articles that were selected for inclusion underwent quality appraisal and data extraction. Once extracted, data from the articles were combined at an aggregate level.</p><p><strong>Results: </strong>The search identified 412 articles. After screening, a total of 16 studies were included in the final review. The overall quality of the studies included was high. Of the 16 articles reviewed, 14 identified significant disparities between racial minority and majority groups and determined that the eligible patients in racial minority groups were less likely to be referred to DXA screening.</p><p><strong>Conclusion: </strong>There is a significant disparity in osteoporosis screening among racial and ethnic minorities. Future efforts should focus on addressing these inconsistencies in screening and removing bias from the healthcare system. Additional research is required to determine the consequence of this discrepancy in screening and methods of equitizing osteoporosis care.</p>","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9465780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Additive Effects of Exercise and Vitamin D Supplementation (with and without Calcium) on Bone Mineral Density in Older Adults: A Systematic Review and Meta-Analysis. 运动和维生素D补充(含钙和不含钙)对老年人骨密度的累加效应:一项系统综述和荟萃分析。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/5570030
Cecilie Fischer, Franz Jakob, Matthias Kohl, Stephanie Kast, Simon Von Stengel, Katharina Kerschan-Schindl, Uwe Lange, Friederike Thomasius, Stefan Peters, Michael Uder, Wolfgang Kemmler

Exercise is a recognized component in the prevention and therapy of osteoporosis. The present systematic review and meta-analysis aimed to determine the effect of Vitamin D (Vit-D) added to exercise versus exercise alone on bone mineral density (BMD) at the lumbar spine (LS) or hip in older adults. A systematic review based on six literature databases according to PRISMA included (a) exercise trials, with an exercise (EX) and a combined exercise + Vit-D group (EX + Vit-D), (b) intervention ≥ 6 months, and (c) BMD assessments at LS or hip. Effects sizes (MD) and 95%-confidence intervals (95%-CI) were calculated using a random-effect model that includes the inverse heterogeneity model (IVhet). Five studies with 281 participants in the EX and 279 participants in the EX + Vit-D were included. No significant differences between EX versus EX + Vit-D were observed for BMD-LS (MD: 0.002, 95%-CI: -0.033 to 0.036) or BMD-hip (MD: 0.003, 95%-CI: -0.035 to 0.042). Heterogeneity between the trial results was moderate-substantial for LS (I2 = 0%) and moderate for hip-BMD (I2 = 35%). The funnel plot analysis suggests evidence for a publication/small study bias for BMD-LS and hip results. In summary, this present systematic review and meta-analysis were unable to determine significant positive interaction of exercise and Vit-D on LS- or hip-BMD. We predominately attribute this finding to (1) the less bone-specific exercise protocols of at least two of the five studies and (2) the inclusion criteria of the studies that did not consequently focus on Vit-D deficiency. This issue should be addressed in more detail by adequately powered exercise trials with promising exercise protocols and participants with Vit-D deficiency. This trial is registered with the International Prospective Register of Systematic Reviews (PROSPERO) ID: CRD42022309813.

运动是预防和治疗骨质疏松症的公认组成部分。本系统综述和荟萃分析旨在确定运动中添加维生素D (vitd)与单独运动对老年人腰椎(LS)或髋关节骨密度(BMD)的影响。根据PRISMA对6个文献数据库进行系统回顾,包括(A)运动试验,运动组(EX)和运动+维生素d联合组(EX +维生素d), (b)干预≥6个月,(c)下肢或髋部骨密度评估。使用随机效应模型(包括逆异质性模型(IVhet))计算效应量(MD)和95%置信区间(95% ci)。5项研究包括281名EX参与者和279名EX + vitd参与者。EX与EX +维生素d在BMD-LS (MD: 0.002, 95%-CI: -0.033 ~ 0.036)或BMD-hip (MD: 0.003, 95%-CI: -0.035 ~ 0.042)方面无显著差异。试验结果之间的异质性在LS (I2 = 0%)和髋-骨密度(I2 = 35%)中为中度。漏斗图分析为BMD-LS和髋关节结果的发表/小研究偏倚提供了证据。总之,本系统综述和荟萃分析无法确定运动和维生素d对LS-或髋关节bmd的显著正相互作用。我们主要将这一发现归因于:(1)五项研究中至少两项的骨骼特异性运动方案较少;(2)研究的纳入标准没有因此关注维生素d缺乏症。这个问题应该通过充分有力的运动试验和有希望的运动方案和维生素d缺乏症的参与者来更详细地解决。该试验已在国际前瞻性系统评价注册(PROSPERO)注册,ID: CRD42022309813。
{"title":"Additive Effects of Exercise and Vitamin D Supplementation (with and without Calcium) on Bone Mineral Density in Older Adults: A Systematic Review and Meta-Analysis.","authors":"Cecilie Fischer,&nbsp;Franz Jakob,&nbsp;Matthias Kohl,&nbsp;Stephanie Kast,&nbsp;Simon Von Stengel,&nbsp;Katharina Kerschan-Schindl,&nbsp;Uwe Lange,&nbsp;Friederike Thomasius,&nbsp;Stefan Peters,&nbsp;Michael Uder,&nbsp;Wolfgang Kemmler","doi":"10.1155/2023/5570030","DOIUrl":"https://doi.org/10.1155/2023/5570030","url":null,"abstract":"<p><p>Exercise is a recognized component in the prevention and therapy of osteoporosis. The present systematic review and meta-analysis aimed to determine the effect of Vitamin D (Vit-D) added to exercise versus exercise alone on bone mineral density (BMD) at the lumbar spine (LS) or hip in older adults. A systematic review based on six literature databases according to PRISMA included (a) exercise trials, with an exercise (EX) and a combined exercise + Vit-D group (EX + Vit-D), (b) intervention ≥ 6 months, and (c) BMD assessments at LS or hip. Effects sizes (MD) and 95%-confidence intervals (95%-CI) were calculated using a random-effect model that includes the inverse heterogeneity model (IVhet). Five studies with 281 participants in the EX and 279 participants in the EX + Vit-D were included. No significant differences between EX versus EX + Vit-D were observed for BMD-LS (MD: 0.002, 95%-CI: -0.033 to 0.036) or BMD-hip (MD: 0.003, 95%-CI: -0.035 to 0.042). Heterogeneity between the trial results was moderate-substantial for LS (<i>I</i><sup>2</sup> = 0%) and moderate for hip-BMD (<i>I</i><sup>2</sup> = 35%). The funnel plot analysis suggests evidence for a publication/small study bias for BMD-LS and hip results. In summary, this present systematic review and meta-analysis were unable to determine significant positive interaction of exercise and Vit-D on LS- or hip-BMD. We predominately attribute this finding to (1) the less bone-specific exercise protocols of at least two of the five studies and (2) the inclusion criteria of the studies that did not consequently focus on Vit-D deficiency. This issue should be addressed in more detail by adequately powered exercise trials with promising exercise protocols and participants with Vit-D deficiency. This trial is registered with the International Prospective Register of Systematic Reviews (PROSPERO) ID: CRD42022309813.</p>","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vertebral Augmentation for Painful Type 4 Osteoporotic Compression Fractures: A Comparative Study. 椎体增强术治疗疼痛性4型骨质疏松压缩性骨折的比较研究。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/1562892
Mohamed Abdelrahman Abdalla, Ricardo Rodrigues, Christian Ulbricht

Background: Type 4 osteoporotic fracture (OF4), according to the classification system of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU), is unstable and requires fixation as per the guidelines of the same group. We evaluated the use of stand-alone vertebral body augmentation (VBA) in pain control of OF4.

Methods: This is a single-centre, in two hospitals, comparative study to evaluate the effectiveness of percutaneous vertebroplasty (PVP) and kyphoplasty (KP) in pain control of OF4. OF4 patients treated with VBA were compared to a conservatively treated control group. The two groups of OF4 were then compared to similar cohort of OF2 and OF3 patients who were treated by either VBA or expectantly.

Results: A total of 78 cases were studied. VBA of OF4 showed a statistically significant better pain control than conservative treatment. The response of this group of fractures to VBA was similar to that of OF2 and 3.

Conclusion: VBA can provide satisfactory pain control for OF4 patients.

背景:根据德国骨科与创伤学会(DGOU)脊柱分会的分类系统,4型骨质疏松性骨折(OF4)是不稳定的,需要按照同组指南进行固定。我们评估了独立椎体增强术(VBA)在OF4疼痛控制中的应用。方法:这是一项在两家医院进行的单中心比较研究,以评估经皮椎体成形术(PVP)和后凸成形术(KP)在控制OF4疼痛方面的有效性。用VBA治疗的OF4患者与保守治疗的对照组进行比较。然后将两组OF4患者与接受VBA或预期治疗的OF2和OF3患者进行比较。结果:共研究78例。与保守治疗相比,OF4的VBA治疗对疼痛的控制有统计学意义。该组骨折对VBA的反应与OF2和of3相似。结论:VBA能较好地控制OF4患者的疼痛。
{"title":"Vertebral Augmentation for Painful Type 4 Osteoporotic Compression Fractures: A Comparative Study.","authors":"Mohamed Abdelrahman Abdalla,&nbsp;Ricardo Rodrigues,&nbsp;Christian Ulbricht","doi":"10.1155/2023/1562892","DOIUrl":"https://doi.org/10.1155/2023/1562892","url":null,"abstract":"<p><strong>Background: </strong>Type 4 osteoporotic fracture (OF4), according to the classification system of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU), is unstable and requires fixation as per the guidelines of the same group. We evaluated the use of stand-alone vertebral body augmentation (VBA) in pain control of OF4.</p><p><strong>Methods: </strong>This is a single-centre, in two hospitals, comparative study to evaluate the effectiveness of percutaneous vertebroplasty (PVP) and kyphoplasty (KP) in pain control of OF4. OF4 patients treated with VBA were compared to a conservatively treated control group. The two groups of OF4 were then compared to similar cohort of OF2 and OF3 patients who were treated by either VBA or expectantly.</p><p><strong>Results: </strong>A total of 78 cases were studied. VBA of OF4 showed a statistically significant better pain control than conservative treatment. The response of this group of fractures to VBA was similar to that of OF2 and 3.</p><p><strong>Conclusion: </strong>VBA can provide satisfactory pain control for OF4 patients.</p>","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10628808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Osteoblast-Specific Overexpression of Nucleolar Protein NO66/RIOX1 in Mouse Embryos Leads to Osteoporosis in Adult Mice. 核仁蛋白NO66/RIOX1在小鼠胚胎成骨细胞特异性过表达导致成年小鼠骨质疏松。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/8998556
Qin Chen, Krishna M Sinha, Benoit de Crombrugghe, Ralf Krahe

In previous study, we showed that nucleolar protein 66 (NO66) is a chromatin modifier and negatively regulates Osterix activity as well as mesenchymal progenitor differentiation. Genetic ablation of the NO66 (RIOX1) gene in cells of the Prx1-expressing mesenchymal lineage leads to acceleration of osteochondrogenic differentiation and a larger skeleton in adult mice, whereas mesenchyme-specific overexpression of NO66 inhibits osteochondrogenesis resulting in dwarfism and osteopenia. However, the impact of NO66 overexpression in cells of the osteoblast lineage in vivo remains largely undefined. Here, we generated osteoblast-specific transgenic mice overexpressing a FLAG-tagged NO66 transgene driven by the 2.3 kB alpha-1type I collagen (Col1a1) promoter. We found that overexpression of NO66 in cells of the osteoblast lineage did not cause overt defects in developmental bones but led to osteoporosis in the long bones of adult mice. This includes decreased bone volume (BV), bone volume density (bone volume/total volume, BV/TV), and bone mineral density (BMD) in cancellous compartment of long bones, along with the accumulation of fatty droplets in bone marrow. Ex vivo culture of the bone marrow mesenchymal stem/stromal cells (BMSCs) from adult Col1a1-NO66 transgenic mice showed an increase in adipogenesis and a decrease in osteogenesis. Taken together, these data demonstrate a crucial role for NO66 in adult bone formation and homeostasis. Our Col1a1-NO66 transgenic mice provide a novel animal model for the mechanistic and therapeutic study of NO66 in osteoporosis.

在之前的研究中,我们发现核仁蛋白66 (NO66)是一种染色质修饰因子,并负向调节Osterix活性和间充质祖细胞分化。在prx1表达的间充质谱系细胞中,NO66 (RIOX1)基因的基因消融导致成年小鼠骨软骨形成分化加速和骨骼变大,而间充质特异性的NO66过表达抑制骨软骨形成,导致侏儒症和骨质减少。然而,体内成骨细胞系中NO66过表达的影响在很大程度上仍未确定。在这里,我们产生了成骨细胞特异性转基因小鼠,过表达由2.3 kB α -1型胶原(Col1a1)启动子驱动的flag标记的NO66转基因。我们发现,在成骨细胞谱系中,NO66的过度表达不会导致发育骨骼的明显缺陷,但会导致成年小鼠长骨的骨质疏松症。这包括长骨松质腔的骨体积(BV)、骨体积密度(骨体积/总体积,BV/TV)和骨矿物质密度(BMD)的减少,以及骨髓中脂肪滴的积累。体外培养来自成年Col1a1-NO66转基因小鼠的骨髓间充质干细胞(BMSCs)显示出脂肪生成增加和成骨生成减少。综上所述,这些数据证明了NO66在成人骨形成和体内平衡中的关键作用。我们的Col1a1-NO66转基因小鼠为研究NO66在骨质疏松症中的作用机制和治疗提供了一种新的动物模型。
{"title":"Osteoblast-Specific Overexpression of Nucleolar Protein <i>NO66</i>/RIOX1 in Mouse Embryos Leads to Osteoporosis in Adult Mice.","authors":"Qin Chen,&nbsp;Krishna M Sinha,&nbsp;Benoit de Crombrugghe,&nbsp;Ralf Krahe","doi":"10.1155/2023/8998556","DOIUrl":"https://doi.org/10.1155/2023/8998556","url":null,"abstract":"<p><p>In previous study, we showed that nucleolar protein 66 (NO66) is a chromatin modifier and negatively regulates Osterix activity as well as mesenchymal progenitor differentiation. Genetic ablation of the <i>NO</i>66 (<i>RIOX1</i>) gene in cells of the <i>Prx</i>1-expressing mesenchymal lineage leads to acceleration of osteochondrogenic differentiation and a larger skeleton in adult mice, whereas mesenchyme-specific overexpression of <i>NO</i>66 inhibits osteochondrogenesis resulting in dwarfism and osteopenia. However, the impact of NO66 overexpression in cells of the osteoblast lineage <i>in vivo</i> remains largely undefined. Here, we generated osteoblast-specific transgenic mice overexpressing a FLAG-tagged NO66 transgene driven by the 2.3 kB <i>alpha</i>-1<i>type I collagen</i> (<i>Col1a</i>1) promoter. We found that overexpression of <i>NO66</i> in cells of the osteoblast lineage did not cause overt defects in developmental bones but led to osteoporosis in the long bones of adult mice. This includes decreased bone volume (BV), bone volume density (bone volume/total volume, BV/TV), and bone mineral density (BMD) in cancellous compartment of long bones, along with the accumulation of fatty droplets in bone marrow. <i>Ex vivo</i> culture of the bone marrow mesenchymal stem/stromal cells (BMSCs) from adult <i>Col1a1</i>-NO66 transgenic mice showed an increase in adipogenesis and a decrease in osteogenesis. Taken together, these data demonstrate a crucial role for <i>NO66</i> in adult bone formation and homeostasis. Our <i>Col1a1</i>-NO66 transgenic mice provide a novel animal model for the mechanistic and therapeutic study of NO66 in osteoporosis.</p>","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9976059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Senolytic Drug Fisetin Attenuates Bone Degeneration in the Zmpste24 -/- Progeria Mouse Model. 抗衰老药物非西汀在Zmpste24 -/-早衰小鼠模型中减轻骨退化。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/5572754
William S Hambright, Xiaodong Mu, Xueqin Gao, Ping Guo, Yohei Kawakami, John Mitchell, Michael Mullen, Anna-Laura Nelson, Chelsea Bahney, Haruki Nishimura, Justin Hellwinkel, Andrew Eck, Johnny Huard
Aging leads to several geriatric conditions including osteoporosis (OP) and associated frailty syndrome. Treatments for these conditions are limited and none target fundamental drivers of pathology, and thus identifying strategies to delay progressive loss of tissue homeostasis and functional reserve will significantly improve quality of life in elderly individuals. A fundamental property of aging is the accumulation of senescent cells. Senescence is a cell state defined by loss of proliferative capacity, resistance to apoptosis, and the release of a proinflammatory and anti-regenerative senescence-associated secretory phenotype (SASP). The accumulation of senescent cells and SASP factors is thought to significantly contribute to systemic aging. Senolytics—compounds which selectively target and kill senescent cells—have been characterized to target and inhibit anti-apoptotic pathways that are upregulated during senescence, which can elicit apoptosis in senescent cells and relieve SASP production. Senescent cells have been linked to several age-related pathologies including bone density loss and osteoarthritis in mice. Previous studies in murine models of OP have demonstrated that targeting senescent cells pharmacologically with senolytic drugs can reduce symptomology of the disease. Here, we demonstrate the efficacy of senolytic drugs (dasatinib, quercetin, and fisetin) to improve age-associated degeneration in bone using the Zmpste24−/− (Z24−/−) progeria murine system for Hutchinson–Gilford progeria syndrome (HGPS). We found that the combination of dasatinib plus quercetin could not significantly mitigate trabecular bone loss although fisetin administration could reduce bone density loss in the accelerated aging Z24−/− model. Furthermore, the overt bone density loss observed in the Z24−/− model reported herein highlights the Z24 model as a translational model to recapitulate alterations in bone density associated with advanced age. Consistent with the “geroscience hypothesis,” these data demonstrate the utility of targeting a fundamental driver of systemic aging (senescent cell accumulation) to alleviate a common condition with age, bone deterioration.
衰老会导致几种老年疾病,包括骨质疏松症(OP)和相关的虚弱综合征。这些疾病的治疗是有限的,没有针对病理的基本驱动因素,因此确定延迟组织稳态和功能储备的进行性丧失的策略将显著提高老年人的生活质量。衰老的一个基本特性是衰老细胞的积累。衰老是一种细胞状态,由增殖能力的丧失、细胞凋亡的抵抗以及促炎和抗再生衰老相关分泌表型(SASP)的释放所定义。衰老细胞和SASP因子的积累被认为是系统性衰老的重要因素。senolytics是一种选择性靶向和杀死衰老细胞的化合物,其特点是靶向和抑制衰老过程中上调的抗凋亡通路,从而导致衰老细胞凋亡并减轻SASP的产生。衰老细胞与几种与年龄相关的疾病有关,包括小鼠的骨密度损失和骨关节炎。先前对小鼠OP模型的研究表明,用抗衰老药物从药理学上靶向衰老细胞可以减轻疾病的症状。在这里,我们通过使用Zmpste24-/- (Z24-/-)早衰小鼠系统治疗Hutchinson-Gilford早衰综合征(HGPS),证明了抗衰老药物(达沙替尼、槲皮素和非瑟酮)改善年龄相关骨变性的功效。我们发现达沙替尼联合槲皮素不能显著减轻小梁骨丢失,而非塞汀可以减少加速衰老Z24-/-模型的骨密度损失。此外,在本文报道的Z24-/-模型中观察到的明显的骨密度损失突出了Z24模型作为概括与老年相关的骨密度变化的翻译模型。与“老年科学假说”一致,这些数据证明了针对系统性衰老的基本驱动因素(衰老细胞积累)的效用,以减轻年龄带来的常见疾病,骨骼退化。
{"title":"The Senolytic Drug Fisetin Attenuates Bone Degeneration in the <i>Zmpste24</i> <sup><i>-/-</i></sup> Progeria Mouse Model.","authors":"William S Hambright,&nbsp;Xiaodong Mu,&nbsp;Xueqin Gao,&nbsp;Ping Guo,&nbsp;Yohei Kawakami,&nbsp;John Mitchell,&nbsp;Michael Mullen,&nbsp;Anna-Laura Nelson,&nbsp;Chelsea Bahney,&nbsp;Haruki Nishimura,&nbsp;Justin Hellwinkel,&nbsp;Andrew Eck,&nbsp;Johnny Huard","doi":"10.1155/2023/5572754","DOIUrl":"https://doi.org/10.1155/2023/5572754","url":null,"abstract":"Aging leads to several geriatric conditions including osteoporosis (OP) and associated frailty syndrome. Treatments for these conditions are limited and none target fundamental drivers of pathology, and thus identifying strategies to delay progressive loss of tissue homeostasis and functional reserve will significantly improve quality of life in elderly individuals. A fundamental property of aging is the accumulation of senescent cells. Senescence is a cell state defined by loss of proliferative capacity, resistance to apoptosis, and the release of a proinflammatory and anti-regenerative senescence-associated secretory phenotype (SASP). The accumulation of senescent cells and SASP factors is thought to significantly contribute to systemic aging. Senolytics—compounds which selectively target and kill senescent cells—have been characterized to target and inhibit anti-apoptotic pathways that are upregulated during senescence, which can elicit apoptosis in senescent cells and relieve SASP production. Senescent cells have been linked to several age-related pathologies including bone density loss and osteoarthritis in mice. Previous studies in murine models of OP have demonstrated that targeting senescent cells pharmacologically with senolytic drugs can reduce symptomology of the disease. Here, we demonstrate the efficacy of senolytic drugs (dasatinib, quercetin, and fisetin) to improve age-associated degeneration in bone using the Zmpste24−/− (Z24−/−) progeria murine system for Hutchinson–Gilford progeria syndrome (HGPS). We found that the combination of dasatinib plus quercetin could not significantly mitigate trabecular bone loss although fisetin administration could reduce bone density loss in the accelerated aging Z24−/− model. Furthermore, the overt bone density loss observed in the Z24−/− model reported herein highlights the Z24 model as a translational model to recapitulate alterations in bone density associated with advanced age. Consistent with the “geroscience hypothesis,” these data demonstrate the utility of targeting a fundamental driver of systemic aging (senescent cell accumulation) to alleviate a common condition with age, bone deterioration.","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10849693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Expression of Concern on "A Radiographic Study on the Associations of Age and Prevalence of Vertebral Fractures with Abdominal Aortic Calcification in Japanese Postmenopausal Women and Men". 对“日本绝经后女性和男性椎体骨折伴腹主动脉钙化的年龄和患病率的x线研究”的关注表达。
IF 1.9 Q3 Medicine Pub Date : 2022-08-02 eCollection Date: 2022-01-01 DOI: 10.1155/2022/9798519
Journal Of Osteoporosis
{"title":"Expression of Concern on \"A Radiographic Study on the Associations of Age and Prevalence of Vertebral Fractures with Abdominal Aortic Calcification in Japanese Postmenopausal Women and Men\".","authors":"Journal Of Osteoporosis","doi":"10.1155/2022/9798519","DOIUrl":"https://doi.org/10.1155/2022/9798519","url":null,"abstract":"<jats:p />","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40608187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Osteoporosis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1